• Home
  • About
  • IMMUNEPlus
  • Research
  • Upcomming Shows
  • Careers
  • Find A Representative
  • Distributors
  • Technology
  • Contact
  • ENDOVAC Bovi Beef
  • ENDOVAC Bovi Dairy
  • ENDOVAC Porci
  • SEPTI Serum Canine
  • ENDOVAC Equi & SEPTISERUM Equine

Research

Supporting Data
Select a product to view product specific supporting data.
Case Studies
Select a product to view product specific supporting data.

Featured Research:

ENDOVAC-Bovi® in Lactating Dairy in Cows

Mastitis occurs in 10% to 12%  of all lactating cows inthe United States, with 30% to
40% of mastitis cows have inflammation due to Escherichia coli. Mastitis costs U.S. dairy
producers more than $1 billion annually.

Click to Download PDF

Effect of Re-17 Mutant Salmonella typhimurium Bacterin-Toxoid on Respiratory Disease and Production

Endotoxemias associated with bovine respiratory disease complex (BRDC) have been effectively controlled in lightweight Holstein feeder steers by Re-17 mutant Salmonella typhimurium bacterin-toxoid (ENDOVAC-Bovi® United States Department of Agriculture-licensed S. Typhimurium Bacterin-Toxoid: IMMVAC, Inc., Columbia, MO).1

Click to Download PDF

Cross-Protection of Feedlot Calves Against Pasteurella Endotoxemia

In this study, 149 lightweight feeder steers were randomly divided into three groups.  All steers were administered appropriate viral vaccines upon arrival and 10 days following arrival.

Click to Download PDF

AGRI-PRACTICE – IMMUNOLOGY

Upon arrival 2,142 feeder calves were divided into two groups. A total of 1,064 head were vaccinated with only one injection of Re-17 mutant Salmonella typhimurium bacterin-toxoid and placed in eight pens adjacent to and alternating with nine pens containing the 1,078 head of nonvaccinated controls.

Click to Download PDF

ENDOVAC-Bovi® in Feedlot Beef Steers

Gram-negative endotoxemia contributes to the signs associated with diarrheal
septicemias, and pneumonias in cattle.

Click to Download PDF


Field Experience With Cross-Protective Anti-Endotoxin Antiserum in Neonatal Calves

Seventeen neonatal calves comprised the ill group for Phase 1 of this study. Phase 2 was comprised of 246 head of normal neonatal calves. Twelve of the 17 ill calves received 0.8 to 1.0 ml/lb of antiserum for treatment of gram-negative diarrhea; 8 of the 12 calves received antibiotics, oral electrolytes, and anti-diarrheal treatment in addition to the antiserum; 3 of the 12 calves received antiserum only; and 1 of the 12 calves received antiserum plus oral electrolyte therapy without concomitant antibiotic therapy.

Read More »
$100 Dollars more for your Feed Lot Steers

Historically ENDOVAC-Bovi® has been the gold standard for protecting neonatal and light weight calves from Gram negative diarrheas and pneumonias. Recent studies have shown that pre-conditioning of feed lot steers with ENDOVAC-Bovi® (IMMVAC, INC., 6080 Bass Lane, Columbia, MO 65201; Ph. 573-443-5363) a) not only reduces the incidence of illness and treatment costs, but b) more importantly increases average weight gain by 143 to 186 pounds over the finishing cycle, thus increasing the bottom line by $143 to $186 per head at today’s prices.

Click to Download PDF

ENDOVAC-Equi® Product Information

Dosage, sizes, features and benefits.

Read More »
ENDOVAC-Bovi® Product Information

Dosage, sizes, features and benefits.

Read More »
SEPTI-Serum® Product Information

Dosage, sizes, features and benefits.

Read More »

«« Back || Next »»

Home | About | IMMUNEPlus | Research | Upcomming Shows | Careers | Find A Representative | Distributors | Technology | Contact
Products: ENDOVAC Bovi Beef | ENDOVAC Bovi Dairy | ENDOVAC Porci | SEPTI Serum Canine | ENDOVAC Equi & SEPTISERUM Equine
(c) 2010 IMMVAC All Rights Reserved.

Powered by WordPress and website design by MayeCreate Design.